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Abstract
The AIDS Cancer and Specimen Resource (ACSR) supports scientific discovery in the area of HIV/
AIDS-associated malignancies. The ACSR was established as a cooperative agreement between the
NCI (Office of the Director, Division of Cancer Treatment and Diagnosis) and regional consortia,
University of California, San Francisco (West Coast), George Washington University (East Coast)
and Ohio State University (Mid-Region) to collect, preserve and disperse HIV-related tissues and
biologic fluids and controls along with clinical data to qualified investigators. The available biological
samples with clinical data and the application process are described on the ACSR web site.
The ACSR tissue bank has more than 100,000 human HIV positive specimens that represent
different processing (43), specimen (15), and anatomical site (50) types. The ACSR provides special
biospecimen collections and prepares speciality items, e.g., tissue microarrays (TMA), DNA
libraries. Requests have been greatest for Kaposi's sarcoma (32%) and non-Hodgkin's lymphoma
(26%). Dispersed requests include 83% tissue (frozen and paraffin embedded), 18% plasma/serum
and 9% other. ACSR also provides tissue microarrays of, e.g., Kaposi's sarcoma and non-Hodgkin's
lymphoma, for biomarker assays and has developed collaborations with other groups that provide
access to additional AIDS-related malignancy specimens. ACSR members and associates have
completed 63 podium and poster presentations. Investigators have submitted 125 letters of intent
requests. Discoveries using ACSR have been reported in 61 scientific publications in notable
journals with an average impact factor of 7.
The ACSR promotes the scientific exploration of the relationship between HIV/AIDS and
malignancy by participation at national and international scientific meetings, contact with
investigators who have productive research in this area and identifying, collecting, preserving,
enhancing, and dispersing HIV/AIDS-related malignancy specimens to funded, approved
researchers at no fee. Scientific discovery has been advanced by this unique biorepository.
Investigators are encouraged to browse the ACSR Internet site for materials to enhance their own
scientific initiatives.
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Background
Human Immunodeficiency Virus (HIV) infection contin-
ues its global spread with almost 40 million HIV-infected
individuals worldwide. More than half are women [1].
While Acquired Immunodeficiency Syndrome (AIDS) is
most associated with opportunistic infections, adults and
children infected with HIV have well-recognized excess
risks for the development of malignancies [2]. Many of
these cancers are associated with known oncogenic viruses
such as: Epstein Barr virus (EBV) with non-Hodgkin's lym-
phoma, human herpes virus 8 (HHV8) with Kaposi's sar-
coma (KS), Hepatitis B (HBV) and Hepatitis C (HCV)
viruses with hepatocellular carcinoma and human papil-
loma virus (HPV) with squamous cell carcinomas of cer-
vix and anal canal. Other cancers, such as lung, are being
studied for their relationship to HIV infection. In the
developed world, cigarette smoking is common and HIV
infected smokers have an increased incidence of smoking-
related cancers of the lip, mouth, and pharynx [3]. With
the advent of highly active antiretroviral therapy (HAART)
in 1996, there was a dramatic reduction in the incidence
of non-Hodgkin's lymphomas (NHL) and especially KS.
However, apparently little reduction is suggested for the
other excess risk cancers including Hodgkin's lymphoma,
squamous cell carcinoma of anus, multicentric Castle-
man's disease in adults and leiomyosarcoma in children.
Despite HAART and public education the total number of
individuals living with HIV in the United States continues
unabated with more than a 50% increase since 1996. HIV
associated cancers in the HAART era are still among the
top causes of death in HIV/AIDS [4]. Furthermore it is of
concern that extended exposure of such a large population
of HIV infected individuals of all ages to nucleoside ana-
logs such as azidothymidine (AZT) and dideoxycytidine
(DDC), as well as, other potent AIDS drugs may induce
DNA damage leading to other significant associations
with cancer in the future.
The need to obtain and provide tumor tissue from
patients with AIDS was originally identified at a confer-
ence on AIDS Lymphoma in May, 1992. The request for a
resource for such specimens was made both by investiga-
tors participating in clinical trials research and laboratory
investigators. Thus the National Cancer Institute (NCI)
established the unique AIDS Malignancy Bank (AMB) in
1994 as a cooperative agreement to collect HIV positive
and control biological specimens, with associated clinical
data, to support translational research into HIV/AIDS-
related malignancies [5]. This AMB program continues as
the AIDS and Cancer Specimen Resource (ACSR) [6], sup-
porting broadened research interests in the area of HIV/
AIDS and oncogenic viruses [7] through collaborative
specimen assemblage. HAART associated reductions in
certain HIV/AIDS-related malignancies make these speci-
mens more difficult to acquire (e.g., KS and NHL), there-
fore the ACSR is a critical conduit for the collection,
preservation, banking and disbursement of scarce HIV/
AIDS-related malignant tissues and biological fluids to
qualified investigators.
In addition to serving as a resource for specimens acquired
from the consortia sites, the ACSR is a national repository
of specimens that reflects the temporal changes, and thus
the history, associated with HIV disease. During the
course of the last decade, the ACSR has established itself
as a singular specialized resource for collection, storage,
and provision of specimens with associated clinical, diag-
nostic, and epidemiologic data collected from HIV-
infected individuals participating in clinical trials, obser-
vational cohort studies, and other research studies con-
ducted by AIDS investigators both domestically and
internationally. During the life of the ACSR, the biorepos-
itory cost of specimens has decreased significantly making
the ACSR a good value to support research by RO1/R21
funded investigators engaged in HIV/AIDS malignancy
studies.
Specimens within the ACSR
The ACSR bank has more than 100,000 specimens from
HIV infected and control patients available from different
processing (43), specimen (15), and anatomical site (50)
types. Specimens are representative of the HIV/AIDS
evolving epidemic and are from a wide variety of patients,
including those with early, as compared to late-stage dis-
ease, multi-site autopsy specimens with involved and
uninvolved tissue, and specimens obtained from patients
with defined anti-retroviral or chemotherapy histories. In
addition, the inventory contains donations from the AIDS
epidemics in developing countries outside the United
States.
Special emphasis specimen and data acquisitions
• Detailed viral typing studies. The ACSR has expanded tis-
sue collection at international sites including Africa, Bra-
zil, and Thailand to obtain specimens from patients who
develop malignancies associated with infection from dif-
ferent subtypes of HIV, HHV-8, EBV, and HPV. These
types of specimens are critical for determining the role of
virus associated carcinogenesis in the natural epidemic
setting, as opposed to clinical settings where there is anti-
viral therapy intervention.
• Neoplastic and non-neoplastic specimens from women.
Gynaecologic tissues, breast, and obstetrical specimens
from HIV-infected women come from collaborative
efforts with ongoing clinical studies of HIV-disease in
women, i.e. Women's Interagency HIV Study (WIHS).
Expansion of this collection to include specimens for
recently discovered agents and unusual malignanciesPage 2 of 20
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study between WIHS and the Rwanda Women's HIV
Study, provides fresh gynaecological specimens (LEEPs,
uterine resections, and biopsies) and biological fluids
from infected women including normal tissue through
cervical cancer.
• Specimens from AIDS-related malignancies clinical treat-
ment trials. AIDS-related malignancy clinical trial groups
(ACTG) obtain specimens that are collected and stored
longitudinally. Samples retained from the early clinical
trials are now available through the ACSR to approved
investigators.
• Specialty sub-bank samples. Disease specific (lymphoma,
KS) tissue micro-arrays (TMAs) for rapid assessment of tis-
sue molecular targets or reagents (antibody, in situ probes,
etc) are available. Specimens preserved specifically for
transmission electron microscopy are available and pro-
vide optimal samples to carry out ultrastructural studies of
malignant, infectious, and reactive tissue processes. Spec-
imens preserved in fixatives recently shown to enhance
immunohistochemical and in situ hybridization results
are currently available or could be developed by request of
approved investigators.
• ACSR data interface. The ACSR has developed a national
computerized database of specimens with patient infor-
mation and clinical history. Over time, this system will
interface with electronic databases of other cooperative
banking groups, as well as with clinical trial groups. A ver-
sion of the ACSR database, stripped of patient identifiers,
is made available online; researchers can search for useful
specimens using various patient, specimen and clinical
criteria.
Investigator use of ACSR samples and clinical data
Investigators made 148 specimen availability inquires to
the ACSR, 88 resulted in full applications and 37 in short
applications. Of the full applications, 73 were approved to
receive multiple samples, 64 received samples, 8 are still
waiting funding or identification of appropriate speci-
mens, and 14 were not approved for a variety of reasons
including scientific merit, sample request size, or lack of
available specimens. The latter investigators were referred
to other bio-repositories or resources, when appropriate.
Of the full approved applications, 83% were for tissue,
18% for serum/plasma and 9% for cell lines, bone mar-
row, or urine. Some applications were approved for mixed
sample types. Of the 37 short form applications received,
36 were approved. The 23 remaining inquires included 19
for which no final application for samples was received
and researcher inquires that were referred to other biolog-
ical sample resources. Requests for Kaposi's sarcoma spec-
imens accounted for 32% of the total served requests,
lymphoma for 26%, and the remainder were for a variety
of other disease types and controls.
Investigators have used the ACSR's HIV infected and non-
infected control biological samples and clinical data to
contribute significant discoveries. Included are: markers
of selective B cell activation during lymphomagenesis [8],
effect of HIV integration site on cancer development [9],
role of macrophages [10], chemokines, cytokines and
growth factors in cancer [11], KHV induced transcrip-
tional reprogramming in KS cell types [12], correlation of
interleukin, CD4+ lymphopenia, viral load and disease
progression [13], persistent infections associated with
cancer, especially EBV [14] and human papillomaviruses
[15] and diagnostic assay development and validation
[16].
Investigations into the pathobiology of HIV infection
have used human tissue to provide translation from
important discoveries made in cell culture or animal stud-
ies. HIV insertion sites within human tissues including
somatic cells [17], macrophages and malignancies [18]
have been defined using ACSR provided infected human
tissue. The neuropathogenesis of AIDS dementia was
explored [19] using HIV infected brain tissue and techni-
cal resources within the ACSR. Likewise human associated
vasculopathy [20] and cardiomyopathy were elucidated
by translation to HIV/AIDS human tissues relevant find-
ings from a "murine AIDS" model [21].
The use of ACSR resources has resulted in sixty-one scien-
tific reports added to the scientific literature and others are
in preparation. Appendix I contains the list of these
reports. Table 1 lists all publishing journals and Figure 1
depicts impact factors for them. Eighty-three podium and
poster presentations have been made at local, national
and international scientific meetings through 2006 by
investigators using/promoting ACSR materials. Appendix
II contains a list of these presentations.
Developments within the ACSR
Evaluation of HIV DNA in ACSR specimens
The ACSR tested the suitability of: banked tissues to eval-
uate in vivo HIV sequences using an HIV bioinformatics
facility. HIV sequence analysis was performed using the
HIVbase® software (GeneJohnson, Inc., St. Augustine, FL).
HIV DNA was identifiable (at copy numbers greater than
1 per 10,000 cells) in:
a) >50% of blood derived T cell preparations
b) >33% of blood CD14+ monocytes
c) AIDS lymphomasPage 3 of 20
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e) kidney and seminal vesicle tissues, and
f) >90% of brain tissues from patients with HIV dementia.
Studies of HIV gene sequence selection/evolution in
human HIV infected tissues from patients with AIDS
malignancies as compared to other classes of HIV related
disease can therefore be facilitated by ACSR resources
[19]. The ACSR has recently begun the development of an
AIDS lymphoma DNA library that can be made available
to interested and qualified investigators.
Tissue micro-arrays from ACSR specimens for translational research
Tissue micro-arrays (TMA) [22] are useful for a wide range
of research interests. One TMA tissue section can provide
diagnostic tissue core sections (0.6 mm in diameter or
greater) from literally hundreds of specimens, e.g., KS and
NHL, from HIV-positive and negative individuals, for
simultaneously testing. Immunohistochemical staining
and in situ hybridization techniques are routinely
employed on TMAs. In general, all ACSR TMAs also con-
tain positive cores (e.g., cell culture lines) and negative
control cores along with the disease specific cores allow-
ing validation of novel tissue biomarkers. The ACSR pro-
vides non-Hodgkin's lymphoma and KS TMA slides to
Table 1: Journals publishing ACSR articles
Journals Weighted*Impact Factor# Number of Articles
Blood 9.654 9
Journal Of Virology 6.034 8
JAIDS – Journal Of Acquired Immune Deficiency Syndromes 3.345 5
Cancer Research 8.727 3
Journal Of Cellular Biochemistry 3.868 3
Nature Medicine 28.010 2
Lancet 20.158 2
Carcinogenesis 9.067 2
AIDS 5.517 2
Journal Of Neuroimmunology 3.598 2
Nature Genetics 24.695 1
JAMA – Journal Of The American Medical Association 9.522 1
Oncogene 6.872 1
American Journal Of Pathology 5.796 1
Cardiovascular Research 5.164 1
American Journal Of Epidemiology 3.978 1
Virology 3.540 1
American Journal Of Physiology – Heart And Circulatory Physiology 3.539 1
Journal Of Clinical Microbiology 3.503 1
AIDS Research And Human Retroviruses 3.069 1
Cellular Immunology 1.988 1
Journal Of Clinical Virology 1.744 1
Cancer Detection And Prevention 1.599 1
Journal Of Infectious Diseases 1.547 1
Anticancer Research 1.331 1
Ultrastructural Pathology 0.918 1
Cellular & Molecular Biology Letters 0.873 1
Articles in journals with impact factors 7.295 55
BMC Medical Informatics And Decision Making 2
Anatomical Record (Part B: New Anat.) 1
Annals Of Diagnostic Pathology 1
Current Opinion In Investigating Drugs 1
Humana Press 1
Articles in journals without impact factors 6
Total articles 61
* The impact factor of a journal varies by year. Each weighted impact factor is calculated by averaging the impact factor from the year of publication 
of each article.
# As impact factors are calculated from citations in a three year window following publication date, the last published impact factor is used for some 
more recent articles.Page 4 of 20
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Impact of ACSR ArticlesFigure 1
Impact of ACSR Articles. Journals that published ACSR related articles are shown with the bubble size representing the 
number of articles (count shown inside bubble) while the width represents the weighted average impact factor. For example, 
Nature Medicine, which published two ACSR articles, is shown at far right because it has the highest impact factor, 28.010.
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Infectious Agents and Cancer 2007, 2:7 http://www.infectagentscancer.com/content/2/1/7approved researchers interested in characterizing these
tumors using applicable tissue probes. Other TMAs are
planned, e.g., various subtypes of lymphoma character-
ized by immunohistochemistry and DNA.
Preview and selection of TMAs by researchers are
enhanced by the development and deployment of virtual
whole slide images of digitized TMA stained sections and
associated clinical data on an ACSR Internet site [23].
Online TMA and tissue core images (as in Figure 2), leg-
ends or data maps, and clinical data are linked for conven-
ient browsing [24,25]. Data is available in an industry
standard XML export format [26]. Printed data maps and
images of TMA slides are also available. TMAs are offered
as an enabling technology to expedite transitional
research in HIV/AIDS and particularly in HIV-related
malignancies, while conserving valuable specimens.
The quality of each TMA is directly related to the individ-
ual donor tissue core characteristics. Older archived paraf-
fin embedded tissues may be antigen negative or weakly
reactive and require optimal antigen retrieval methods
and high antibody titres for positive results. Core donor
tissues specifically prepared by optimal fixation and
processing provide the most favourable TMA sections for
studies with novel probes. Donor tissue characteristics are
available with each TMA to provide guidance to the inves-
tigator. Cut sections from each TMA are stained by H & E
to assure the presence of target tissues and by appropriate
immunohistochemical stains (IHC) to assure tissue
immunoreactivity for expected molecular targets prior to
listing TMA availability on the Internet site.
Structure
Organization of the ACSR
The national ACSR was formed as a cooperative agree-
ment between the NCI, Office of the Director, Division of
Cancer Treatment and Diagnosis (DCTD) and regional
ACSR consortia: University of California, San Francisco
for the West Coast, George Washington University for the
East Coast and The Ohio State University for the Mid-
Region. The ACSR steering committee, comprised of the
principal investigators from each consortium, developed
policies and procedures for standardized operation across
the organization. An outside Research Evaluation and
Decision Panel (REDP), comprised of experts in the field,
evaluates requests for specimens as shown in Figure 3. See
[6] for a detailed description of the program.
Privacy, Confidentiality, Authorization and Consent
Local Institutional Review Boards (IRBs) approve and
monitor the activity of each ACSR site. The local ACSR
maintains a research protocol to protect biologic sample
donor privacy and to maintain confidentially of clinical
data as required by federal standards including the
requirements of HIPPA [27]. Local IRB approval is
required for participation in the national ACSR program.
ACSR Internet site and national database
The ACSR established a database containing information
on ACSR specimen types and associated clinical data
obtained from patients with HIV/AIDS-related malignan-
cies and control specimens. Each consortium sends elec-
tronic de-identified data quarterly to the central ACSR
database. Records are maintained at each local site in
accordance with the local IRB approved protocol. Some
specimen collections have other databases that enable
investigators to perform studies on specimens linked with
a defined clinical or epidemiologic pedigree.
Guidelines
The ACSR has quality practices for biorepository opera-
tion that are consistent with International Society for Bio-
logical and Environmental Repositories (ISBER) best
practices [28], NCI Office of Biorepositories and Biospec-
imen Research (OBBR) guidelines [29] and AIDS Clinical
Trials Group (ACTG) Biomedical Research Institute (BRI)
guidelines [30].
Marketing
The ACSR has strategies to market the availability of HIV/
AIDS-associated malignancy specimens. Through word of
mouth, directed mailings, newsletters, and presence
(handouts and a specially designed ACSR booth) at
national and international meetings, the ACSR reaches
increasing numbers of potential researchers interested in
utilization of the resource and have steadily increased the
number of applications. The ACSR seeks feedback from its
investigator community to identify future needs, gaps,
and shortcomings.
Specimen disbursement
Identifying researcher needs
Investigators search on-line (using the Specimen Search
web page [6]) to identify specimen types that meet their
research requirements. Once researchers find specimens
of interest, they fill out a Letter of Intent (LOI) application
for acquiring the specimens. The ACSR has two applica-
tion types (short and long form) depending on the
number of specimens needed. All of the requirements for
researchers are available on the above Internet site. If the
researcher is unsure of whether needed samples and data
are available or has other questions regarding specimen
and data availability, the ACSR or NCI program director
can be contacted. Some of the general potential uses of
ACSR specimens are outlined in Table 2.
Letters of Intent and tracking
Full and short form LOI applications are accepted from
investigators throughout the year. Forms can be down-Page 6 of 20
(page number not for citation purposes)
Infectious Agents and Cancer 2007, 2:7 http://www.infectagentscancer.com/content/2/1/7
Page 7 of 20
(page number not for citation purposes)
Sample TMA image from the virtual microscope section on the ACSR Mid-region Internet site for viewing TMS core tissues by interested investi atorsFigur  2
Sample TMA image from the virtual microscope section on the ACSR Mid-region Internet site for viewing TMS core tissues by 
interested investigators.
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Infectious Agents and Cancer 2007, 2:7 http://www.infectagentscancer.com/content/2/1/7loaded from the Letter of Intent Application Form web page
[6]. The application process requires minimal paper work
and is outlined in detail on the web site. When specimens
are approved for delivery, they are packaged and shipped
(on dry ice, when appropriate) according to International
Air Transport Association (IATA) regulations. The ACSR
works with other biological material resources and refers
investigators to these resources if specimens are not avail-
able within the ACSR cooperative group. The confidential
ACSR LOI tracking system allows inquiry tracking, provid-
ing details of requests and the status of shipments without
disclosing research directions outside of the ACSR staff.
Sample Quality control
Investigators who receive ACSR specimens assist in the
ACSR Quality Assessment Program by evaluating the
quality of specimens they receive and returning a written
evaluation document to the ACSR. For example, users
have reported that blood stored by the ACSR yielded
>90% high quality RNA and DNA and viability of PBMCs
exceeding 50% in samples stored for up to five years. A
return evaluation card is included with each sample ship-
ment.
Random samplings of specimens are regularly tested for
preservation of RNA and DNA and the viability of cells in
frozen storage. Many of the banked specimens, however,
are too small to allow extensive pre-testing that requires
destructive sampling. The quality of stored biological
samples can generally be anticipated based on specimen
type, type of fixative or processing, length of storage, stor-
age method and the type of testing anticipated by the
investigator [31,32]. Investigators are encouraged to verify
the use of specified biological sample types before under-
taking their planned study.
Cost to investigators
Samples are provided to approved, funded investigators
working in non-profit research settings at no fee. Investi-
gators working in a commercial setting may also obtain
samples if approved by the REDP but a fee per sample and
for service may be applied.
Table 2: Potential uses of ACSR banked specimens
Type Use
Autopsies (multi-site) frozen & fixed DNA and protein studies within individuals; involved vs. uninvolved tissues
Tissue array analyses Comparison of antigen expression between 
many patient tumors
Diseased tissue specific cytokine, virus, antigen 
expression
Frozen lymphoma, KS and tumor tissues DNA, RNA, and protein array studies; viral discovery/strain variation studies
Non Hodgkin's lymphoma (AIDS & non-AIDS) 
epidemiology study (serum & fixed tissue)
Serologic studies on cases vs. controls for cytokine, viral antigen, serum proteins. Coupled with 
epidemiologic data in collaboration with Dr. Elizabeth Holly test disease associations, risk factors, 
transmission risk factors, resistance factors, lymphoma tissue, DNA/protein correlation with 
serum factors/disease associations.
AIDS Malignancy Consortium clinical trial 
specimens
Longitudinal, trial associated specimens for analyses of disease specific markers in collaboration 
with AMC
Serum specimens from cross-sectional survey 
in Thailand
Studies on low KS prevalence untreated HIV & serum cohort Infected vs. uninfected age & sex 
matched specimen comparisons
Studies on HIV, non-US viral isolates. Repeat blood draws from HIV+ individuals available for rate 
of variation studies.
Ano-genital specimens from men and women 
HIV+/HIV-
Study role of HIV strains in early stages of ano-genital carcinogenesis
Plastic embedded tissue suitable for 
transmission electron microscopy
Evaluation of virus identity, morphogenesis, and cytopathology in various disease statesPage 9 of 20
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Specimens from a wide variety of HIV infected patients
and selected controls are processed based on laboratory
standard protocols described in the ACSR standard oper-
ating procedure manual, accessible through the Process
Specimens (Protocols) web page [6]. This manual provides
instructions for the collection, preparation and shipment
of specimens among the ACSR sites and to approved
investigators. Cooperative groups interfacing with the
ACSR can use the ACSR manual as a resource for their
activities.
Specimens donated individually
Each ACSR site has developed a consortium of patholo-
gists and clinicians at participating sites who collect and
contribute specimens and clinical information to the
ACSR. If samples are specifically collected for the ACSR,
each donor signs an ACSR informed consent document
and a HIPPA document approved by the local IRB. Sam-
ples from archived paraffin embedded tissues and associ-
ated clinical data are acquired according to local hospital
rules, IRB approved protocols including federal HIPPA
waiver of informed consent for use of personal medical
information preparatory to research [27]. All samples and
clinical data are coded when they are entered into the
local ACSR site, de-identified before being placed on the
web and all samples and clinical data released to investi-
gators are anonymous.
Samples donated by HIV/AIDS treatment and 
epidemiology groups
The ACSR is directly affiliated with the AIDS Malignancy
Consortium (AMC) [33], a national group that conducts
clinical trials in patients with AIDS-related malignancies.
This affiliation allows the banking of well-characterized,
longitudinal specimens from a variety of clinical trials for
ultimate use by approved researchers. This association
provides material for the search for prognostic markers
and promising therapeutic regimens. Using the AMC rela-
tionship as a model, further group affiliations have been
developed, such as relationships with the Women's Inter-
agency HIV Study (WIHS), the AIDS Clinical Trials Group
(ACTG), the San Francisco gay men's health study, the
national ano-genital cancer study, San Francisco lym-
phoma study of 1600 NHL patients and 2500 random
controls, natural history study of HHV8/KSHV in homo-
sexual men in the San Francisco area, the Rwanda HIV
women's study, and a variety of smaller studies. The WIHS
is a unique study, which provides interval blood speci-
mens and fresh colposcopy specimens from 2809 HIV-
positive and 959 negative women who have cervical
lesions. This study provides valuable pre and post diag-
nostic biologic specimens.
Specimen collections donated or accessed through a 
referral process
Where large collections of specimens are in place within
established programs, the ACSR can act as a broker
between the ACSR research applicant and the "resource"
tissue bank. Where there are biologic sample collections
that have been placed at risk because of funding loss, tis-
sue bank down sizing or other reasons, the ACSR can
accept transfer of banked biological sample collections
with their attendant databases, for inclusion in the overall
ACSR program. Examples of the first type of relationship
includes: interfaces with the National Neuro AIDS Bank
(NNAB), the National Neurological disease Tissue Con-
sortium (NNTC), the UCLA Brain Bank Program, various
multi-center AIDS cohort study (MACS) groups, the UCSF
AIDS Specimen Bank (ASB) and the Hawaiian AIDS natu-
ral history cohort study. Examples of the second type,
where specimens have been transferred to the ACSR
include: the San Francisco gay men's HHV-8 natural his-
tory cohort, and the US Department of Defence Thailand
vaccine trial serum specimen bank.
The ACSR approach to the changing epidemic
The USA alone has about 950,000 people living with HIV
infection (about a quarter of whom are not aware of their
infection). Prospective and longitudinal samples across
the time-line of the changes in the epidemic are critical to
understanding the epidemic as it evolves. Collection of
such specimens has been a goal of the ACSR. The ACSR is
taking into consideration the evolution of HIV-associated
cancers (e.g., the higher rate of head and neck cancer in
HIV patients in Africa) by establishing pertinent collabo-
rations. Through collaboration, the ACSR is reaching out
to heavily HIV/AIDS affected areas, such as Africa, Brazil,
Russia, and Thailand to acquire relevant specimens.
Conclusion
The ACSR makes available large numbers of HIV/AIDS-
related malignancy specimens for funded, approved
researchers at no fee. Scientific discovery has been
advanced by this unique program through promotion of
interest in and access to HIV/AIDS human tissues for pri-
mary and translational research. Investigators using ACSR
specimens have shared their discoveries with the scientific
community through publications in notable scientific
journals and at meetings. Investigators are encouraged to
browse the ACSR Internet site or contact the ACSR for
specimens to enhance their own scientific initiatives.
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